Medicinal – Page 46

Effect on consumers’ sustainable purchase intention of dietary supplement purine labeling

mycolabadmin

This study examined how labeling the purine content on dietary supplements affects whether consumers continue buying them long-term. Researchers found that clearly showing purine levels encourages people to make sustainable choices, especially those concerned about gout or similar health conditions. The effect works by making health-conscious consumers more aware of potential risks and connecting their purchases to both personal health and environmental values.

CORRECTION: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

mycolabadmin

A major research study examining psilocybin’s effectiveness for treating depression has been corrected due to mathematical and data handling errors. The researchers fixed these issues by recalculating statistics and removing duplicate data from their analysis. While the main conclusions remained similar after correction, the authors emphasize this research is still preliminary and should lead to further study before clinical use.

Research progress of edible mushroom polysaccharide-metal trace element complexes

mycolabadmin

This research reviews how edible mushroom polysaccharides can be combined with essential metals like iron, selenium, and zinc to create health-boosting supplements. These complexes improve how our bodies absorb and use these important minerals, offering benefits like better immune function, antioxidant protection, and potential cancer-fighting properties. Scientists are studying different ways to make these complexes and testing their effectiveness for treating various health conditions.

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

mycolabadmin

This study directly compared two popular psychedelic drugs, LSD and psilocybin (magic mushrooms), in 28 healthy volunteers. Researchers found that these substances produce very similar mental effects when given at equivalent doses, with the main difference being that LSD lasts longer. The study establishes that about 20 milligrams of psilocybin is roughly equivalent to 100 micrograms of LSD. These findings could help guide dosing for future psychiatric treatments using these psychedelics.

Toxicology and Analysis of Psychoactive Tryptamines

mycolabadmin

Tryptamines are a growing class of psychoactive drugs that can cause hallucinations and other dramatic changes in perception. These substances, including compounds like DMT and psilocybin from magic mushrooms, work by affecting serotonin receptors in the brain. While some research explores their potential medical use for treating depression and anxiety, they also carry serious risks including dangerous changes in heart rate, body temperature, and mental state. Scientists have developed new laboratory methods to detect these drugs in blood and urine samples to help doctors diagnose and treat overdoses.

A novel synbiotic formulation prevents calcium oxalate stones by restoring gut microbiota homeostasis

mycolabadmin

This study tested a special probiotic and prebiotic combination to prevent kidney stones caused by too much oxalate in the body. The formula containing three beneficial bacteria strains and a plant-based fiber worked better than any single component alone. The treatment restored healthy gut bacteria, protected the intestinal lining, and reduced the amount of oxalate reaching the kidneys, effectively preventing stone formation in animal models.

Pharmacokinetics of Psilocybin: A Systematic Review

mycolabadmin

This review examines how the body processes psilocybin, a compound from magic mushrooms being studied for treating depression and anxiety. When taken orally, psilocybin is quickly converted to its active form, psilocin, which reaches peak levels in the bloodstream within 1-4 hours and is eliminated mainly through urine. The body’s ability to process psilocybin involves specific liver enzymes that vary between individuals, potentially explaining why people respond differently to the same dose and why certain medications can interfere with its effects.

Fungal Microbiome Diversity in Urban Forest Decreases Asthma and Allergic Inflammation

mycolabadmin

This study found that living near urban forests with diverse fungal species may protect against asthma. Researchers collected fungi from air samples in Seoul and found that areas with more forests had fewer asthma cases. Laboratory tests showed that fungi from forests were better at reducing allergic inflammation than fungi from city centers. The diversity of fungal species, rather than specific types, appeared to provide protective benefits.

Antioxidative Activities of Micronized Solid-State Cultivated Hericium erinaceus Rich in Erinacine A against MPTP-Induced Damages

mycolabadmin

Researchers tested a processed form of Lion’s mane mushroom (Hericium erinaceus) to see if it could protect against Parkinson’s disease-like damage in mice. The mushroom mycelium was specially processed to break down cell walls and increase its effectiveness. When given to mice exposed to a Parkinson’s-causing toxin, the mushroom treatment restored dopamine levels and reduced harmful oxidative stress in the brain and liver in a dose-dependent manner.

Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity

mycolabadmin

Researchers tested how different psychedelic drugs affect brain electrical activity in rats using EEG recordings. They found that psilocin, LSD, mescaline, and DOB all produced similar patterns of decreased brain activity and reduced communication between brain regions. Importantly, these effects in rats closely matched what scientists observe in human brain studies, suggesting that rats can be useful for understanding how psychedelics work in the brain.

Research Topic: Medicinal